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The evolutionarily conserved Notch signaling pathway regulates crucial aspects of 
development and tissue homeostasis. This thesis contributes research towards understanding 
a role of non-canonical Notch signaling in the tumor-stroma interaction of breast cancer, 
provides a bioinformatics-based technology to study these interactions, and proposes a novel 
mouse model of the liver disease in Alagille syndrome. 
In Paper I, we report a novel target for non-canonical Notch signaling in breast cancer, the 
cytokine IL-6. In human breast cancer cell lines, we observe increased IL-6 mRNA and 
protein levels when Notch signaling is amplified, in turn activating the JAK/STAT pathway 
in a p53-dependent, but CSL-independent fashion, via IKKα and IKKβ of the NF-κB 
pathway. These data add a new facet to the existing body of knowledge on hyperactivated 
Notch signaling in promoting inflammation in breast tumors. 
In Paper II, we present and validate a new bioinformatics-based approach of species-specific 
sequencing (S3). Using an intermixed human tumor and mouse stroma cell population from 
xenografted cells, we demonstrate a way to decode transcriptomes, separated by their species-
specific differences, with 99% accuracy. This technique circumvents current problems in 
mechanically separating mixed tissue, and paves the way to efficiently analyze in vivo cell-
cell interactions.  
In Paper III, we characterize a mouse strain, with a missense mutation in the Jagged1 gene, 
as a potential model for the rare genetic disorder Alagille syndrome. We show that this model 
recapitulates pathologies in the liver, heart, lens and kidney observed in Alagille patients, and 
identify dysregulated biliary morphogenesis caused by this mutation. We also use the S3 
technology, developed in Paper II, to investigate signaling specifically in receptor-expressing 
cells by wild type and mutated Jagged1. 
In summary, the work presented in this thesis sheds new light on the role of Notch signaling 
in breast cancer and liver disease, and provides a novel technology to facilitate the detailed 
study of cell-cell interactions.  
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As with all living things, the human body is on a constant quest for homeostasis, a state 
where many variables are balanced so conditions remain stable. The Swedish term lagom, 
meaning ‘just the right amount’, aptly encapsulates this concept, where a homeostatic body 
represents just the right balance of conditions to achieve the state of health. Diseases can 
occur when this balance is not achieved, when there is too little or too much. Cancer is an 
example of ‘too much’, where cells undergo uncontrolled growth, but there are also disorders 
of ‘too little’ where loss or misplacement of cell types or structures is seen.  
The struggle for achieving and maintaining optimal homeostasis begins before birth, during 
development, when the body plan is being laid out. Dysregulation of cues necessary for 
normal body plan formation can lead to an overproduction or underproduction of specific 
factors leading to a plethora of diseases of varying severity, affecting diverse organs. The 
struggle continues post-birth when achieving and maintaining the ‘just right’ homeostatic 
balance of cells in each organ. Dysregulation of cues responsible for this balance can lead to 
an equal plethora of diseases where cells are lost or overproduced. 
Information essential to homeostasis, and thus health, is exchanged within and between cells 
via signaling pathways. Notch signaling is a critical line of this cellular communication and 
has been implicated in both cancer and developmental disorders. This thesis contributes to 
understanding roles of Notch signaling in maintaining homeostasis, specifically how its 
dysregulation (a) mediates the interaction of tumor cell and stroma in breast cancer, and (b) 
leads to bile duct breakdown in the liver disease of Alagille syndrome, as well as (c) 
providing a useful technology to study these roles. 
Each topic covered in this introduction is a field of biology in and of itself; therefore for the 
sake of clarity and brevity, I will highlight aspects of each topic as it pertains to the papers 












No man is an island, entire of itself; every man is a piece of the continent, a part of the main. 
– Meditation XVII (excerpt) by John Donne c.1624 
A core concept of nature is that all aspects of a system are connected. Specific to biology, 
cells live in a community, acting on and reacting to their surroundings, i.e. no cell is an 
island.  
Cells have evolved efficient diversity generating mechanisms, which we call signaling 
pathways, to relay this information. Cell communication starts with a signal-sending 
component, called a ligand (often a molecule, protein, lipid or ion) that interacts with a 
signal-receiving component called a receptor (molecule that responds to specific ligands), 
which initiates a signal transduction (biochemical chain of events in response to an initial 
signal, creating a targeted response).  
These signals can be classified as being within, among or between cells, as follows:  
• IntracrineA signals produced by the cell stay within the cell itself. 
• Autocrine signals produced by the cell are secreted (exit the cell membrane), and 
affect the cell itself, or a neighbor of the same cell type, via receptors on the cell 
surface. An example of this is shown in Paper I. 
• Juxtacrine signals produced by the cell interact with adjacent, touching cells. This can 
be via ligand-receptor interactions or gap junctions, and are capable of affecting either 
cell, or both. The canonical Notch signaling pathway, introduced in the next section, 
uses this mode of signaling with membrane-anchored ligands and receptors. Papers 
I-III address different aspects of this pathway.  
• Paracrine signals produced by the cell affect other cells in close proximity. Examples 
include neurotransmitters, the major signaling molecules for the nervous system, and 
cytokines for the immune system. The latter is shown in Paper I. 
• Endocrine signals produced by the cell affect distant cells, transported by the 
cardiovascular or lymphatic system. Hormones are the major signaling molecules for 
the endocrine system. 
In this thesis, several of these modes of signaling are addressed, with Notch signaling as the 
common denominator. In Paper I, we study the signaling in breast cancer, and identify the 
cytokine interleukinB-6 (IL-6) as a target of non-canonical Notch signaling. In Paper II, we 
present a novel RNA-Seq-based bioinformatics tool that distinguishes the transcriptomes of 
signal-receiving cells from signal-sending cells, in a mixed species scenario. In Paper III, we 
                                                
A intra, within (Latin); krinein, to separate (Greek); autós, self (Greek); iuxta, alongside 
(Latin); pará, next to (Greek); éndon, inside (Greek)   
B Interleukin: coined in 1979 by Dr. Vern Paetkau; derives from inter, between (Latin) and 
leukin, produced by and acts on leukocytes (Green, 1988) 
 
 3 
elucidate the effects of a specific mutation in the Jagged1 ligand of the Notch pathway, 
similar to what is seen in the human condition, Alagille syndrome. 
‘THE TEMPLE OF NOTCH’C 
The Notch pathway is a member of the ‘Signaling Seven’ 
of evolutionarily conserved signaling mechanisms 
crucial for early embryonic development, but with such 
importance comes great responsibility, as dysregulation 
of these pathways are also critical drivers of disease. The 
other six members are Wnt, TGF-β, Hedgehog, 
JAK/STAT, nuclear hormone receptors and receptor 
tyrosine kinase pathways (Barolo and Posakony, 2002; 
Penton et al., 2012). 
Discovery 
Notch signaling is a cell-cell contact dependent pathway (Figure 1D) and is a major regulator 
of cell fate during development. In DrosophilaE, there is one receptor (Notch) and two 
ligands (Serrate and Delta), and in C. elegansF there are two receptors (Lin-12 and Glp-1) and 
one ligand (Lag-2). In mammals, there are four Notch receptors (Notch 1-4) and five 
canonical ligands: Jagged (Jag) 1, 2 and Delta-like (Dll) 1, 3, 4 (Kopan and Ilagan, 2009). 
First described in 1914 by John S. Dexter as a heritable abnormality of ‘perfect notched 
wings’ in Drosophila melanogaster (Dexter, 1914), the alleles of the Notch gene were 
identified three years later by Thomas Hunt Morgan (Morgan, 1917). Almost 70 years later, 
the laboratories of Spyros Artavanis-Tsakonas (Artavanis-Tsakonas et al., 1983) and 
Michael W. Young (Kidd et al., 1983) independently deciphered the first Notch receptor 
gene sequence by cloning the Drosophila Notch locus. Drosophila Delta (Vassin and 
Camposortega, 1987) was the first ligand to be sequenced, followed by Drosophila Serrate 
(Fleming et al., 1990) and C. elegans Lag-2 (Henderson et al., 1994). In 1991, Leif W. 
Ellisen and colleagues first demonstrated the existence of Notch signaling in humans, 
connected to human health, when they discovered that the unknown gene displaying 
chromosomal translocations in T cell acute lymphoblasic leukemia (T-ALL) was the human 
homolog of the Drosophila Notch receptor (Ellisen et al., 1991). Since this time, the roles 
and functions of Notch signaling have become an ever-increasing field of study, and nearly 
25 years later, new roles of Notch signaling are still being discovered. Detailed knowledge of 
                                                
C The name of a ‘world’ by Disco, dedicated to Minecraft's creator Markus Persson 
D Figure 1: also conceptualized by Prof. Isabella Screpanti at the first international Notch 
meeting, EMBO Workshop on Notch Signalling in Development and Cancer (2005)  
E Drosophila: fruit fly, model organism 
F Caenorhabditis elegans: roundworm, model organism 
Figure 1: Adapted from The Creation 
of Adam (Michelangelo, 1508-12) 
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the canonical and non-canonical roles of this pathway could unlock novel insights into human 
development and disease. 
Canonical Notch signaling in mammals 
The Notch pathway is unique, in that it does not use an amplifying signal, but rather relies on 
sequential steps to convey extracellular input to intracellular gene expression. Notch 
signaling is often viewed as a gatekeeper against differentiation, maintaining cells in a more 
stem-cell-like state, although in some cellular contexts, such as skin, it can act in a 














In the canonical Notch pathway (Figure 2), the signal-sending cell expresses transmembrane 
DSL (Delta/Serrate/Lag-2) ligands that bind to the transmembrane Notch receptor on a 
neighboring, signal-receiving cell. DSL ligands can activate signaling through the Notch 
receptors in trans (cell-cell interaction) or inhibit signaling in cis (interaction within in the 
same cell) (D'Souza et al., 2008). Ligand binding leads to the cleavage of Notch by ADAM 
(a disintegrin and metalloprotease) proteases at site 2 (S2). The Notch extracellular domain 
(NECD), along with the activating ligand, is shed and endocytosed into the signal-sending 
cell. The Notch intracellular domain (NICD) is released in the signal-receiving cell upon 
cleavage by the -secretase complex at site 3 (S3) near the inner plasma membrane, and at 
site 4 (S4) within the transmembrane domain. The NICD translocates to the nucleus, where it 
interacts with the DNA-binding protein CSL (CBF1/Suppressor of Hairless/Lag-1), also 
referred to as RBP-J  in mammals (Furukawa et al., 1992), and acts as a transcription co-














factor along with other co-activators, such as Mastermind-like (MAML1) (Kopan and Ilagan, 
2009).  
We have only recently begun to understand the diversity in the Notch downstream responses. 
Transcriptional targets of Notch signaling tend to be context-specific, with indicative target 
genes differing dependent on the cell type studied, but traditional transcriptional targets 
include the Hes (Iso et al., 2001) and Hey (Maier and Gessler, 2000) gene families, which 
encode basic helix-loop-helix transcription factors (recommended reviews: Andersson et al., 
2011; Kopan and Ilagan, 2009). We have developed a tool, presented in Paper II, which can 
be used to learn more about the downstream consequences of Notch signaling by performing 
RNA-Seq on a human and mouse mixed-species co-culture of ligand-expressing and 
receptor-expressing cells. 
Evolutionary conservation of Notch receptors and ligands 
The Notch signaling pathway is highly evolutionarily conserved, with true receptors and 
ligands emerging in Metazoa (Gazave et al., 2009). Drosophila, C.elegans and mammalian 
Notch receptors and ligands share most of the same functional domains (further explained in 
the Ligand-receptor interaction section). The basic difference between Drosophila Notch 
(dNotch) and the four mammalian Notch paralogs (mNotch1-4) is the number of epidermal 
growth factor-like (EGF)-repeats (29-36) that each receptor contains, with dNotch and 
mNotch1-2 highly similar (Kopan and Ilagan, 2009). The differences between the species are 
indeed important for function, but the mammalian Notch components share very high 
sequence similarity, for example human and mouse receptors and ligands of the Notch 
pathway share 83-97% similarity in protein sequences (Table 1-2). Human and mouse 
fragments are used to experimentally activate the Notch pathway (expanded in The Notch 
Toolbox section), and are able to be interchanged because they are considered to be 
functionally identical.  
  NCBI accession number 
(Number of amino acids, aa) 
IdentityG Table 1:                     
Notch receptors.                   
Data compiled from 
Pairwise Alignment 
































                                                
G Identity: proportion of pairs of identical residues between two aligned sequences over the 




  NCBI accession number 
(Number of amino acids, aa) 
Identity 
Table 2:           
Notch ligands. 































The Jagged and Delta ligands are characterized by a DSL domain, EGF-repeats and 
transmembrane domain (TMD). The signal activating interaction between Notch ligands and 
the Notch receptors occurs by non-covalent association of EGF-repeats 11-12 of the receptor 
with the DSL domain of the ligand (Rebay et al., 1991; Shimizu et al., 1999), but it is 
important to note that, although the DSL domain is required for binding, it is not sufficient for 
promoting signal initiation (Cordle et al., 2008). An evolutionarily conserved valine in EGF-
repeat-8 is essential for ligand selectivity between Serrate/Jagged and Delta family ligands 
(Yamamoto et al., 2012), and Dll4 binds with greater affinity than Dll1 to Notch1 EGF-
repeats 6–15 (Andrawes et al., 2013). Figure 3 illustrates the domains of the Notch receptors 
and ligands. It would be valuable to know the downstream effects of each specific ligand-
receptor combination, but information is limited in this area, foremost due to the plethora of 
cell-specific responses and a dearth of ligand- and receptor-specific detection tools 
(Andersson and Lendahl, 2014). 
It is hypothesized that a mechanical pulling force is needed for the Notch extracellular 
domain (NECD) to be released from the cell membrane after ligand interaction (Meloty-
Kapella et al., 2012; Nichols et al., 2007), therefore the use of soluble ligands is 
controversial in the field. The signaling activity from these soluble ligands has been attributed 
to the fact that the ligand is actually tethered to extracellular matrix (ECM) components, such 
as microfibril-associated glycoprotein 2 (MAGP2), providing the stabilization needed for the 
required pulling forces (D'Souza et al., 2008; Nehring et al., 2005). The changes in protein 
structure due to mechanical pulling force can be thought of as a coil being pulled, revealing 
spaces and structural components that can be accessed by molecules and affect subsequent 
steps in the signal transduction.  
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Bidirectional signaling, where receptor-binding causes activation of signaling in the ligand-
expressing cell as well (e.g. the Eph-ephrin pathway) (Pasquale, 2008) is less definitive in 
Notch signaling. This may be due to the relatively small intracellular domain of the ligands, 
or because current tools require some knowledge of specific transcription factors or 
downstream events. Without this knowledge, it is a bit like finding a needle in a haystack to 
verify whether this occurs. The tool developed in Paper II could provide a way to investigate 
the possibility of Notch backward-signaling in distinct cell contexts, by specifically 
generating the transcriptome of the ligand-expressing cell. 
  
Figure 3: Receptors and ligands of the canonical Notch pathway.                                                          
EGF, epidermal growth factor-like; LNR, Lin12-Notch repeats; NRR, negative regulatory region; HD, 
heterodimerization domain; TMD, transmembrane domain; RAM, RBP-J  association module; ANK, ankyrin 
repeats; NLS, nuclear localization sequence; PEST, proline/glutamic acid/serine/threonine-rich motifs; DSL, 
Delta/Serrate/LAG-2; DOS, Delta and OSM-11-like proteins; C, cysteine                                                    





























Non-canonical Notch signaling in mammals 
Non-canonical Notch is broadly classified as any DSL-independent, non-DSL ligand 
interaction, CSL-independent or non-nuclear-NICD signaling, as well as direct interaction 
with components of other signaling pathways (Andersen et al., 2012; D'Souza et al., 2010; 
Heitzler, 2010).  
The number of reports of non-canonical Notch signaling in mammals is growing, ranging 
from direct interaction of NICD with Smad3 in Notch-TGFβ crosstalk (Blokzijl et al., 2003) 
or NICD with components of the hypoxia pathway (Poellinger and Lendahl, 2008), to non-
nuclear NICD involved in abrogating Bax-induced apoptosis (Perumalsamy et al., 2010), and 
CD4+ T cell activation and proliferation regulated by Notch1 independent of CSL (Dongre et 
al., 2014).  
Non-canonical Notch signaling has been linked to breast tumor progression, for example, 
hyperactive Notch4 in CSL-deficient mammary tissue induces mammary tumors (Raafat et 
al., 2008). We contribute another example in Paper I, where we show that CSL-independent 
and non-nuclear-NICD-initiated Notch signaling activates IL-6 expression and JAK/STAT 
signaling in p53-mutated breast cancer cells.  
Crosstalk with other pathways 
There are thought to be just under 20 signal transduction pathways responsible for generating 
every cell type, pattern and tissue in metazoans (Barolo and Posakony, 2002; Gazave et al., 
2009; Gerhart, 1999; Pires-daSilva and Sommer, 2003). Each contains a unique set of 
components, all of which are encoded in the genomes of every animal. These pathways 
increase the diversity of their output by interaction, or crosstalk, with each other.  
The Notch pathway is simple, with relatively few components, yet it participates in many 
diverse processes. One way versatility is achieved is through extensive interaction with other 
pathways (Poellinger and Lendahl, 2008), therefore studying this crosstalk contributes to our 
knowledge of Notch’s role in development as well as understanding disease progression and 
designing combination therapies. NICD interacts with intracellular components of many 
pathways, including nuclear factor (NF)-κB (Shin et al., 2006; Wang et al., 2001), 
BMP/TGFβ (Blokzijl et al., 2003; Dahlqvist et al., 2003; Itoh et al., 2004), Wnt (Axelrod et 
al., 1996; Espinosa et al., 2003; Hayward et al., 2005) and Hedgehog pathways (Dave et al., 
2011; Schreck et al., 2010; Xie et al., 2013), as well as the cellular hypoxic response 
(Coleman et al., 2007; Gustafsson et al., 2005; Sahlgren et al., 2008; Zheng et al., 2008).  
Tumor protein p53 
p53 is a tumor suppressor whose activation is triggered by acute DNA damage or 
hyperproliferative signals, and responds by activating pathways of cell cycle arrest, DNA 
repair, apoptosis and senescence (Bieging et al., 2014).   
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Since Notch plays an important role in cancer, and p53, considered the ‘guardian of the 
genome’ (Lane, 1992), is mutated in over 50% of cancers (Vogelstein et al., 2000), it is not 
difficult to see that these two major biological players influence one another. The 
transactivating form of another tumor protein, p73α, is known to physically interact with 
NICD thereby inhibiting CSL-mediated transcription (Hooper et al., 2006). Recently, it was 
shown that compromised CSL and p53 function promotes cancer-associated fibroblast 
activation (Procopio et al., 2015). In Paper I, we show a link between Notch, NF-kB, p53 
and IL-6 (expanded in the Cytokine signaling in tumor and stroma section). 
The Notch Toolbox 
The present-day scientist has a comprehensive set of tools for studying the Notch signaling 
pathway, including gene expression plasmids, pathway activity reporters, inhibitors, 
recombinant proteins, modified cell lines and mouse models, all of which are utilized in the 
work of this thesis. Future tools could include Notch-related genome engineering by the 
CRISPR/Cas9 system (Jinek et al., 2012), as already shown for Notch in Drosophila via 
conditional mutagenesis (Xue et al., 2014). 
Plasmids 
Expression constructs of Notch pathway components can be transfected into cells to activate 
or inhibit signaling. In addition to the full-length form of the Notch receptor (NotchFL), 
many genetically modified versions have been developed, for example the NotchΔE (lacking 
the ECD) is constitutively cleaved by γ-secretase in the absence of ligand and thus sensitive 
to γ-secretase inhibitors (GSIs), and NICDΔRAM (lacking the RAM domain) cannot interact 
with CSL. Dominant negative mutants of the Notch transcriptional activation complex have 
also been developed, for example the dominant negative CSL (R218H, arginine-to-histidine 
replacement at position 218) that can bind to NICD but not to DNA, and dominant negative 
MAML that cannot recruit other transcription complex components thereby effectively 
blocking Notch signaling. 
Notch transcriptional reporter constructs are frequently used to monitor Notch activity in cells 
and tissues. Commonly used promoters to drive Notch-dependent reporters, such as luciferase 
or fluorescent proteins, are based either on endogenous targets (e.g. Hes, Hey) or multimeric 
CSL-binding sites (e.g. 12xCSL-Luciferase (Kato et al., 1997)) (Ilagan and Kopan, 2014). 
Inhibitors 
Manipulating the Notch pathway at any point from receptor maturation to receptor-ligand 
interaction, NICD release or cofactor recruitment would affect its signaling output. Current 
therapeutic interventions focus on inhibiting receptor-ligand interactions and interfering with 
the proteolytic processing of the receptors (Groth and Fortini, 2012; Shao et al., 2012). 
Notch inhibitors have been developed as potential therapeutic interventions, but are also 
valuable tools when studying the signaling pathway. The γ-secretase complex is responsible 
for releasing the NICD, and GSIs, such as DAPT, are used to block this cleavage, abrogating 
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canonical Notch signaling in the cell (Berezovska et al., 2000). GSIs are pan-Notch-receptor 
inhibitors, which can sometimes be disadvantageous if studying specific receptor roles in 
cells or tissue expressing several Notch receptors (De Kloe and De Strooper, 2014). In 
contrast to GSIs, blocking antibodies able to inhibit Notch signaling can target individual 
Notch receptors (Gordon and Aster, 2014) or ligands (Koga and Aikawa, 2014).  
The first drug to undergo a phase I clinical trial was a GSI in 2006 (Deangelo et al., 2006), 
but was discontinued due to gastrointestinal toxicity in patients. In addition to other GSIs, 
meant to block the release of the NICD by the γ-secretase complex, current drug development 
approaches target specific Notch receptors and ligands with antibodies designed to block 
interaction or lock the structure from proceeding with the signal cascade (Wu et al., 2010). 
There is yet to be a successful ‘Notch drug’ on the market, let alone a candidate continuing to 
later-phase clinical trials (Andersson and Lendahl, 2014). 
Recombinant proteins 
The immobilized ligand assay is used to present DSL ligands to Notch-
expressing cells for in vitroH analysis of the activated pathway. Engineered 
ECDs of ligands fused to the Fc domain of immunoglobulin G (IgG) 
antibodies are tethered to Protein-G-coated tissue culture plates (Varnum-
Finney et al., 2000) (Figure 4). In this setting, the orientation of the 
immobilized ligands, more so than ligand density, is an important factor for 
active signaling (Andersson and Lendahl, 2014; Goncalves et al., 2009; 
Toda et al., 2011). Also, the Fc domain of the fusion proteins induces 
dimerization, which may explain why soluble ligands have been reported to 
activate Notch signaling (Czajkowsky et al., 2012). 
Modified cell lines 
Expression constructs for all receptors and ligands, as well as many 
constituent components, of the Notch pathway have been used to transfect 
cell lines. Co-culturing receptor-expressing cells with ligand-expressing 
cells (Figure 5) can be used to activate, measure and study ligand-induced 
Notch signaling, Paper II explores the distinct transcriptomes between 
Notch activation by immobilized ligand and by co-culture. 
Mouse models 
There are a large number of different transgenic mouse lines generated to cause constitutive 
or conditional loss or gain of function of many components of the Notch pathway, as well 
Notch signaling reporter lines to visualize Notch-responsive cells in mice (Gridley and 
                                                
H in vitro: in glass, (Latin) refers to studying molecules or cells outside their biological 









Groves, 2014). For example, the R26-STOP-NICD mouse (Murtaugh et al., 2003) can be 
used to study the role of elevated Notch signaling in a cell- or tissue-directed manner when 
crossed with a promoter-specific Cre mouse (e.g. WAP-Cre to activate whey-acidic-protein-
expressing cells in the mouse mammary gland). Mice can also model Notch-driven diseases. 
There are 4 Jagged1 point mutations that cause inner-ear defects in mice: Headturner 
(G289D, glycine-to-aspartic-acid replacement at position 289) (Kiernan et al., 2001), Slalom 
(P269S, proline-to-serine replacement at position 269) (Tsai et al., 2001), Ozzy (W167R, 
tryptophan-to-arginine replacement at position 167) (Vrijens et al., 2006) and Nodder 
(H268Q, histidine-to-glutamine replacement at position 268) (Hansson et al., 2010). The 
Nodder missense mutation sits in the Delta and OSM-11-like protein (DOS) domain (Figure 
3), at EGF repeat-2 of Jagged1. Paper III explores the hypomorphicI signaling of this 
Jagged1 mutation and its effects on the development of many of the same organs 
symptomatic in Alagille syndrome.  
  
                                                
I Hypomorph: a type of mutation causing a partial loss of gene function through reduced 
expression or functional performance (Muller, 1932). 
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NOTCH SIGNALING IN DISEASE 
Since the first indication of dysregulated Notch signaling driving disease was shown when 
Notch mutations were associated with T-ALL, the list has grown to include cancer, immune 
disorders, developmental syndromes, stroke and cognitive symptoms. Activating NOTCH1 
mutations have been implicated in chronic lymphocytic leukemia (CLL) (Fabbri et al., 2011; 
Puente et al., 2011). Mutations in DLL3 (Bulman et al., 2000) and associated Notch pathway 
components (Sparrow et al., 2006; 2008; Whittock et al., 2004) cause skeletal defects in 
spondylocostal dysostosis. Cognitive dysfunctions, such as CADASIL syndrome, can be 
caused by NOTCH3 mutations (Joutel et al., 1996). Mutations in JAG1 (Li et al., 1997; Oda 
et al., 1997), in the majority of cases, or in NOTCH2  (McDaniell et al., 2006), can cause 
Alagille syndrome, the subject of Paper III. 
Alternative splice variants occur when exons are combined in different ways to produce more 
than one gene product from the same locus. Alternative splicing of Notch pathway 
components is seen in normal mammalian development, but it also plays a role in disease 
progression. Alternative splicing of NOTCH2 and CSL (RBPJ in mammals) is frequently 
observed in genome-wide studies of AML (acute myeloid leukemia) (Adamia et al., 2014; 
Lobry et al., 2014). Table 3 lists the total number of variants, as well as the number of 
protein-coding transcripts for each receptor and ligand of the canonical Notch pathway. With 
many genes listed having fewer than half of their transcripts as protein-coding, it would be 
interesting to study if the non-protein coding variants also have a regulatory role.  
 Gene 
(human) 
Total # of transcripts 
(splice variants) 
# of protein-coding 
transcripts 
Table 3:                        
Data compiled             
using Ensembl         






 NOTCH1 3 1 
NOTCH2 8 4 
NOTCH3 6 3 





JAG1 9 2 
JAG2 5 2 
DLL1 2 2 
DLL3 5 3 












RBPJ 31 22 
NUMB 32 19 
MAML1 4 1 
MAML2 2 2 
MAML3 3 3 
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Poor patient prognosis in breast cancer has been linked to many dysregulated components of 
the Notch pathway: loss or inactivation of the Notch negative regulator NUMB (Pece et al., 
2004; Stylianou et al., 2006), elevated JAG1 expression (Reedijk et al., 2005), enhanced 
Notch signaling after tamoxifen treatment (Rizzo et al., 2008), activating gene 
rearrangements in Notch receptors (Robinson et al., 2011), NOTCH1 and NOTCH4 
overexpression in triple-negative breast cancer (TNBC) (Speiser et al., 2012). Notch in breast 
cancer is studied in Paper I and II. 
BREAST CANCER 
Cancer is a complex disease, with tumors having heterogeneous gene expression, histology 
and clinical outcome. A recent study found a strong correlation between the number of cell 
divisions of normal self-renewing cells in a particular tissue with the lifetime risk of cancer in 
that tissue, with only one third of the variation in a tissue’s cancer risk attributable to 
environmental factors or inherited predispositions, leaving the majority due to ‘bad luck’, i.e. 
random mutations (Tomasetti and Vogelstein, 2015). 
Douglas Hanahan and Robert Weinberg proposed that the complexities of this disease can be 
described in terms of a set of six underlying principles, or ‘acquired capabilities’ during 
tumor development, dubbed the ‘hallmarks of cancer’ (Hanahan and Weinberg, 2000): self-
sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis (shown 
with Notch in breast epithelial cells (Meurette et al., 2009)), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. In addition, they identified 
cancer-specific metabolism and immune evasion as emerging hallmarks, and genomic 
instability and tumor-promoting inflammation as enabling characteristics (Hanahan and 
Weinberg, 2011). In order to successfully investigate these capabilities in all cancer types, 
with the goal of finding novel therapeutic targets to allay and eventually ablate tumorigenesis, 
robust and reproducible models must be in place.  
The normal human mammary gland has a system of ducts and lobules. The lobules are 
organized into approximately 20 lobes, drained by collecting ducts that converge at the 
nipple. Each lobule is made of acini that form the terminal duct lobular units (TDLUs), which 
are the functioning secretory units of the mammary gland. The acini and ducts consist of a 
surrounding basement membrane, an outer layer of myoepithelial cells, an inner layer of 
polarized luminal epithelial cells, and a central lumen. Outside the basement membrane is the 
stroma, which consists of connective tissue, blood vessels, fat and nerves (Nilsson et al., 
2001). Breast cancer is a disease in which malignant neoplasia forms in the ducts and lobules 
of the breast. 
As with most glandular organs, the mammary gland is in a stroma of mesenchymal cells, 
such as fibroblasts, adipocytes, immune cells and ECM. The ECM provides structural 
support, and directs the organization of the cytoskeleton through transmembrane receptor 
signaling to keep tissue integrity intact (Bissell et al., 2005). For example, myoepithelial cells 
from ductal carcinoma in situ (DCIS) show gene expression variation and epigenetic changes 
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compared to myoepitheial cells from normal breast tissue (Allinen et al., 2004; Hu et al., 
2005). Furthermore, normal and malignant mammary cells grown in two-dimensional 
monolayer cultures on tissue culture plastic without any ECM lose their tissue-specific 
function and morphological organization (Weigelt and Bissell, 2008). 
The basement membrane in breast tissue, composed mainly of laminin and type IV collagen, 
is a specialized form of the ECM that functions as structural support, and plays a role in 
regulating proliferation, organization and differentiation (Leblond and Inoue, 1989). 
Regardless of the histological type of the tumor, breast malignancies arise mainly in the 
TDLU. Carcinomas show a loss of epithelial polarity and tissue organization. Changes in 
cellular composition associated with a normal mammary gland progressing to an invasive 
carcinoma include the loss of myoepithelial cells, an increased number of in myofibroblasts 
and immune cells in the stroma, and enhanced vascularization. (Weigelt and Bissell, 2008). 
Clinical overview 
According to the latest (2012) World Health Organization GLOBOCAN project report, 
estimating cancer incidence, mortality and prevalence worldwide, breast cancer is the second 
most common cancer in the world, comprising 25% (1.67 million new cases) of all cancers 
diagnosed and over 0.5 million deaths in 2012. The mortality rate in less developed regions is 
1.6 times higher than in more developed regions (Ferlay et al., 2015).  
Breast cancer is not a single disease, but rather a diverse collection of histopathologies, 
genetic and genomic variations, and clinical outcomes. Several genetic perturbations are 
important for breast cancer, including loss of or mutation in p53, mutations in BRCA genes 
(which codes for the breast cancer type susceptibility protein) and the signaling status of 
human epidermal growth factor receptor 2 (HER2) (Vargo-Gogola and Rosen, 2007), as well 
as the expression levels of cell-cell junction proteins such as Claudin and E-cadherin (Perou, 
2011).  
Figure 6: Molecular subtypes of breast cancer.                                                                                     
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2; 
CK: cytokeratin; EGFR: epidermal growth factor receptor.                                                              
(adapted from Prat and Perou, 2009; Sandhu et al., 2010)  
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One way to classify breast carcinomas into specific subtypes is according to their gene 
expression profile: Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like and 
Normal Breast-like (Prat and Perou, 2011). The molecular subtypes of breast cancer are 
illustrated in Figure 6. Each subtype’s prognosis and treatment response is different (Sørlie et 
al., 2001). The luminal A and B subtypes are sensitive to hormone therapy like tamoxifen (a 
small molecule antagonist of the estrogen receptor), while luminal B and HER2+ subtypes 
can be treated with the trastuzumab (Herceptin®), a monoclonal antibody that interferes with 
the HER2/neu receptor. Basal and claudin-low subtypes, more aggressive and difficult to 
treat, are associated with poor prognosis (Badve et al., 2011; Herschkowitz et al., 2007). 
There are four types of standard treatment, used often in combination: surgery, radiation 
therapy, hormone therapy, and chemotherapy. Hormone therapies include estrogen receptor 
antagonists and aromatase inhibitors. There are several promising chemotherapeutic 
strategies designed as adjuvant therapies, including monoclonal antibodies and tyrosine 
kinase inhibitors (National Cancer Institute, 2015). 
In humans, breast cancer metastasizes mostly to the lung, bone and liver. Less common sites 
are the brain, kidney, spleen and heart (Weigelt et al., 2005). Between 60% and 70% of 
women who succumb to breast cancer have had it eventually spread to their lungs, and in 
21% of cases, the lung is the only site of metastasis (Horak and Steeg, 2005; Minn et al., 
2005). 
Notch plays an important role in cell fate decisions, promoting cell-fate commitment along 
the luminal lineage of the developing mammary gland (Bouras et al., 2008; Politi et al., 
2004; Raafat et al., 2011). It is becoming increasingly evident that dysregulated Notch 
signaling is linked to breast cancer, where Notch is rarely mutated but frequently hyper-
activated (Mutvei et al., 2015). For example, upregulation of Notch signaling is found in 
several forms of breast cancer (Pece et al., 2004; Stylianou et al., 2006), and tamoxifen 
treatment in breast cancer therapy may in fact elevate Notch signaling as an unwanted side 
effect (Rizzo et al., 2008). Notch negative regulation by Numb is relevant for normal 
mammary tissue homeostasis, and when skewed, contributes to oncogenesis, as shown by a 
“high Notch/low Numb” signature in breast cancers (Pece et al., 2004; Stylianou et al., 
2006). In the mouse, directed overexpression of activated Notch in the mammary gland 
results in breast tumors (Raafat et al., 2004). There are emerging hallmarks of cancer now 
being explored in the context of breast cancer, including cellular energetics (Hanahan and 
Weinberg, 2011), where dysregulated Notch activity leads to a glycolytic switch in breast 
tumor cells, and elevated Notch signaling correlates with more invasive growth in breast 
tumor xenograft experiments (Landor et al., 2011). The role of Notch signaling in tumor-






When a plant goes to seed, its seeds are carried in all directions; but they can only live and 
grow if they fall on congenial soil.  
 – Stephen Paget (Paget, 1889) 
Paget’s seed and soil hypothesis speaks to the importance of studying the ‘congenial soil’, or 
stroma, of a tumor. Cancer-associated fibroblasts, endothelial cells, pericytes, lymphocytes, 
myeloid cells and ECM populate a tumor’s microenvironment (Pietras and Östman, 2010). 
Not only the primary tumor, but also the site of its metastasis, requires a permissive site for 
colonization (Horak and Steeg, 2005). Understanding communication between tumors and 
their stroma, for example by cell-cell interactions and cytokine signaling, can lead to 
developing treatment strategies to make this stroma less habitable.  
Cytokine signaling in tumor and stroma 
One of the first identified cytokines, IL-6, has a pro-inflammatory 
function in stimulating immune responses during infection and 
inflammation. It acts as an anti-inflammatory myokine (cytokine 
produced from muscle) in response to muscle contraction (Febbraio 
and Pedersen, 2005). IL-6 is mainly produced by innate immune cells 
and B cells, but is also secreted by many non-leukocyte cell types 
such as fibroblasts and malignant cells (Hirano, 1998), and its 
production is regulated by NF-κB signaling (Libermann and Baltimore, 1990). Elevated 
levels of IL-6 are associated with chronic inflammation, including rheumatoid arthritis and 
Crohn’s disease (Rincon, 2012), as well as liver and colon cancers (Mauer et al., 2015). In 
breast cancer patients, elevated serum IL-6 levels correlate with poor outcome (Bachelot et 
al., 2003; Sansone et al., 2007; Sethi et al., 2011; Wang et al., 2005). Since hyperactivated 
Notch and elevated IL-6 levels are seen in breast cancer, we explore if Notch signaling can 
lead to IL-6 expression in Paper I. 
Breast cancer models 
Models commonly used to investigate breast cancer include cell lines, xenografts and 
genetically engineered mice (Polyak, 2007; Vargo-Gogola and Rosen, 2007), the first two of 
which are discussed below as they pertain to the thesis.  
Cell Lines 
Using cell lines for cancer research has a number of advantages, including the fact that they 
are easy to handle, continuously divide so they can be grown in vast quantities, and can be 
revived from cryogenic freezing to restart experiments years later. Also, by working with 
commonly used cell lines, new findings can be compared to those reported in the field.  




That being said, these same points have disadvantages as well. Cell lines grown in continual 
culture are prone to phenotypic and genotypic drift, because of the selective advantage of 
more rapidly growing clones within the cell population (Burdall et al., 2003). Also, cell lines 
are sensitive to culture conditions, especially the inclusion or exclusion of growth factors, 
which can alter their cell phenotype, differentiation, signaling pathway activation and gene 
expression (Birgersdotter et al., 2005; Streuli et al., 1991; Yamada and Cukierman, 2007). 
Databases, such as the Broad Institute’s Cancer Cell Line Encyclopedia (CCLE) (Barretina et 
al., 2012), are helpful resources for detailed genetic characterization of human cancer cell 
lines. 
The pros and cons above also hold true for breast cancer cell lines. An additional limitation is 
that patient biopsies of breast tumors are heterogeneous, yet relatively homogeneous cell lines 
are routinely used in breast cancer research. Overall, when chosen appropriately and cultured 
correctly, cell lines can continue to be used as powerful experimental tools (Geraghty et al., 
2014; Holliday and Speirs, 2011). 
The MCF-10A (from the Michigan Cancer Foundation) (Soule et al., 1990) immortalized 
normal breast epithelial cell line, and the breast cancer cell lines MCF-7 (Soule et al., 1973) 
and MDA-MB-231 (from the MD Anderson Cancer Center) (Cailleau et al., 1974) are 
among the most common tools used in breast cancer research. Additional cell lines used in 
Paper II include: MDA-MB-175 VII (Cailleau et al., 1974), Sk-Br-3 (Engel and Young, 
1978), T-47D (Engel and Young, 1978; Keydar et al., 1979), HCC38 (Gazdar et al., 1998), 
and Hs578T (Hackett et al., 1977). Table 4 summarizes several characteristics of the breast 
cancer cell lines used in this thesis. 











MCF-7 IDC L M (PE) + + – WT 
T-47D IDC L M (PE) + + – MUT 
MDA-MB-175 VII IDC L M (PE) + – – WT 
Sk-Br-3 IDC L / HER2 M (PE) – – + MUT 
MDA-MB-231 IDC B  M (PE) – – – MUT 
Hs578T CS B  P – – – MUT 
HCC38 DC B P – – – MUT 
MCF-10A nc B Breast  – – – WT 
Table 4: Characterization of breast cancer cell lines used in this thesis. IDC: invasive ductal 
carcinoma; CS: carcinosarcoma; nc: not cancer (immortalized normal breast epithelium); L: luminal; B: 
basal; M (PE): metastasis (pleural effusionJ); P: primary tumor; ER: Estrogen receptor (+, present; -, 
absent); PR: Progesterone receptor (+, present; -, absent); HER2: oncogene encoded by ERBB2 
gene (+, amplified; -, absent or low); WT: wildtype; MUT: mutant. (compiled from Finn et al., 2009; 
Lacroix and Leclercq, 2004; Lacroix et al., 2006; Subik et al., 2010) 
                                                




Although ‘mice are not little humans’ (Jonkers and Derksen, 2007), the laboratory mouse is 
the best compromise as a mammalian model organism for studying human disease, because 
of physiological and genetic similarities, and relative ease of genetic manipulation. Mice for 
studying human cancer fall into either transplantation or transgenic models. Transplantation 
can be done by allograftingK (mouse cells into mouse) or xenograftingL (human cells into 
mouse) (Jonkers and Derksen, 2007), the latter of which is used in Paper II. 
Both the transplantation and transgenic models are useful, but neither is ideal to study the 
entire cancer pipeline from gene to drug discovery. Each has its advantages and limitations, 
which should be considered when interpreting their data.  
Allograft and transgenic, or genetically engineered, models share the benefit of not exhibiting 
graft versus host immune reactions (Outzen and Custer, 1975; Ozzello et al., 1974), which is 
a problem when using xenografts, but come with the drawback that mice tend to develop 
mesenchymal tumors, whereas human age-related cancers mostly are of epithelial origin 
(DePinho, 2000). Xenografts are often used to test cancer drugs to study their effect on 
human, rather than mouse, tumors (Richmond and Su, 2008).  
OrthotopicM (grafting tissue in its natural position) xenografts of human tumors are popular in 
cancer research, but the technique is restricted to immune-compromised (e.g. athymic nude 
mice lacking certain T cell responses) or immunodeficient (e.g. SCID mice lacking T- and B-
cell responses) animals to avoid the graft versus host reactions, mentioned above. 
Consequently, the role of an intact immune system in tumor formation and progression 
cannot be studied in these mice. Xenografts of human tumors in humanized mice have been 
developed (Kuperwasser et al., 2004; 2005) to provide a more realistic tumor 






                                                
K állos, other (Greek) 
L xenos, foreign (Greek) 




First described in the 1970s by Daniel Alagille (Alagille et al., 1975), Alagille syndrome 
(AGS) is an autosomal dominant genetic disorder, diagnosed primarily by clinical findings 
followed by sequence analysis to detect the precise genetic aberration. The disease is 
traditionally defined clinically by cholestasis (due to insufficient bile ducts in the liver) and 
congenital heart disease, in addition to abnormalities in the skeleton, eye, kidney and a 
characteristic facial phenotype. Other, less frequently seen, features target the ear, intestine 
and pancreas (Crosnier et al., 2000; Dhorne-Pollet et al., 1994; Hingorani et al., 1999; 
Kamath et al., 2004; Li et al., 1997; Martin et al., 1996; Oda et al., 1997). Figure 8 
illustrates the variety of organs affected in AGS. 
Clinical overview 
AGS is caused mainly by missense and nonsense mutations (almost 90% of cases) or 
deletions (approximately 5-7% of cases) in JAG1 (AGS type 1), but also by mutations 
(approximately 1% of cases) in NOTCH2 (AGS type 2) (McDaniell et al., 2006; Online 
Mendelian Inheritance in Man, 1986; Spinner et al., 2000b; Turnpenny and Ellard, 2012). 
Categorized as a rare disease, AGS 
afflicts approximately 1 in 30-70,000 
newborns, based on liver disease 
diagnoses in infants. This may be an 
underestimated prevalence, as some AGS 
patients do not develop liver disease 
during infancy (Kamath et al., 2010; 
National Library of Medicine US, 2015). 
Approximately 30-50% of AGS patients 
have an inherited mutation, while about 
60-70% have a de novoN mutation 
(Spinner et al., 2000a). Palliative care 
treatment for AGS patients is focused on 
surgical and medical treatments for liver 




                                                
N de novo: anew, beginning again (Latin). A de novo mutation is a gene alteration present for 
the first time in one family member as a result of a germ line mutation (Pagon et al., 1993). 
Figure 8: Organs affected in Alagille syndrome. 
Solid lines highlight organs also affected in the 
Nodder mouse (Paper III).                                 






















There are currently five transgenic mouse models identified as exhibiting Alagille syndrome-
associated phenotypes:  
− inner ear phenotype by a missense mutation in Jag1 on a C3HeB/FeJ background: 
Headturner (Jag1Htu/+) (Kiernan et al., 2001), Slalom (Jag1Slm/+) (Tsai et al., 2001) 
and Ozzy (Jag1Ozzy/+) (Vrijens et al., 2006). 
− liver, heart, eye and kidney phenotypes in a Jag1/Notch2 double heterozygous mouse 
(Jag1dDSL/+, Notch2del1/+) on a mixed C57BL/6J-129S1/SvImJ background (Lozier et 
al., 2008; McCright et al., 2002). 
− liver phenotype by vascular smooth muscle-specific deletion of Jag1 (SM22-
Cre:Jag1flox/flox) on a C57BL/6J background (Hofmann et al., 2010). 
− heart phenotype by endothelial-specific deletion of Jag1 (VE-Cadherin-
Cre:Jag1flox/flox) on a C57BL/6J background (Hofmann et al., 2012). 
− craniofacial phenotype by cranial neural crest-specific deletion of Jag1 (Wnt1-
Cre:Jag1flox/flox) on a C57BL/6 background (Humphreys et al., 2012). 
A recent study this year introduced a mouse model heterozygous for Jag1 (Jag1dDSL/+) on a 
C57BL/6J background, with congenital cholangiopathy due to impaired intrahepatic bile duct 
development (IHBD), which could be rescued by glycosyltransferase Poglut1 (Rumi) deletion 
(Thakurdas et al., 2015). 
The Nodder mouse, named after the nodding behavior and balance defects in the 
heterozygous state (Jag1Ndr/+) on a pure C3HeB background, is a Jagged1 mutant identified 
from a large-scale ethylnitrose urea (ENU) mutagenesis screen. Its mutation is located at the 
second EGF-like repeat of the Jagged1 ECD, a location which carries missense mutations in 
AGS (Krantz et al., 1998; Li et al., 1997; Oda et al., 1997; Spinner et al., 2000a), and 
encodes a histidine-to-glutamine replacement at position 268 (H268Q). The Jag1Ndr ligand 
has specifically lost its capacity to bind to Notch1 in trans and activate signaling (Hansson et 
al., 2010). In Paper III, we propose the homozygous Nodder mouse (Jag1Ndr/Ndr) on a mixed 
C3HeB/FeJ-C57BL/6J background as a novel model for AGS type 1 that recapitulates the 









Notch in bile duct development 
In the human liver, hepatocytes (liver bulk), the biliary tree and the hepatic portal vein system 
are arranged in hexagonal functional units called lobules. Before bile ducts develop, only 
hepatoblasts (hepatocyte progenitor cells) surround the portal mesenchyme and associated 
endothelial cells. Bile duct development starts with ductal plate formation, a single layer of 
cholangiocyte (epithelial cells of the bile duct) precursors, which are derived from the 
hepatoblasts in direct contact with the portal mesenchyme. The ductal plate then duplicates, 
and small pockets (lumen precursors) develop between the two layers, which then form bile 
ducts with mature cholangiocytes (Figure 9). 
Notch signaling coordinates hepatoblast to cholangiocyte differentiation and tube formation 
during bile duct development (Lemaigre, 2010). In mice, inhibiting Notch signaling results in 
reduced biliary differentiation, whereas activating Notch promotes biliary differentiation 
from hepatoblasts (Zong et al., 2009). When Hes1 is inactivated, a ductal plate develops but 
does not form tubes (Kodama et al., 2004), and when CSL is inactivated after ductal plate 
formation, tubulogenesis is impaired and leads to bile duct paucity (Zong et al., 2009). 
Notch2 has a dominant role in bile duct formation, promoting biliary differentiation and 
tubulogenesis (Sparks et al., 2010; Tchorz et al., 2009), and intact Notch signaling is 
necessary for post-natal maintenance of bile duct structures (Sparks et al., 2011). 
‘Rise of the organoids’ (Willyard, 2015) 
All cells in the body are in a three-dimensional environment, but two-dimensional culturing 
of cells on plastic plates in a growth factor-enriched medium has been the staple of basic and 
Figure 9: Intrahepatic bile duct formation.                                                                                                 
(adapted from Gordillo et al., 2015; Zorn, 2008) 
Mouse:     E12.5            E13.5    E17.5              Perinatal
Human:     50 days            56-58 days   14 weeks             30 weeks 
Portal mesenchyme   Endothelial cells   Hepatoblasts
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biomedical research. There is a strong argument for the importance of assaying cells ex vivoO 
in a physiologically relevant environment, to recapitulate cell-cell interactions and maintain 
morphology (Weigelt and Bissell, 2008). A popular substrate-of-choice is Matrigel®, a 
laminin-rich extracellular matrix (lrECM) extracted from basement-membrane-producing 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells (Kleinman and Martin, 2005). 
From cells to organs, the 21st century brought with it an inspired concept of growing 
rudimentary mini-organs in the dish, where researchers could study everything from 
development to cancer therapeutics. Laboriously tinkering with needed growth factors and 
culture conditions, scientists have grown organoids for components of many tissues, 
including the cerebral cortex, intestine, optic cup, pituitary gland, kidney, liver, pancreas, 
neural tube, stomach, prostate, breast, heart and lung (Willyard, 2015). 
In Paper III, we generate bile-duct-enriched liver organoids (Huch et al., 2013; 2015) as a 
model to study bile duct morphogenesis defects in the Nodder mice. In the biliary organoid 
culture set-up (Figure 10), isolated bile duct fragments are embedded in Matrigel® and 
medium supplemented with a precise growth factor cocktail. Less than 24 hours after 
isolation, the edges of the cylindrical ducts fuse and the organoids swell, ballooning out. 
Organoids are passaged by manual disruption, broken apart into tiny sheets of cells, which 




                                                
O ex vivo: from living, (Latin) refers to tissue from an organism cultured in an external 
environment  




The central dogma of molecular biology (Crick, 1970) 
explains the flow of genetic information in an organism 
(Figure 11). It states that DNA encodes RNA 
(transcription), which encodes protein (translation). The 
traditional techniques to detect these components have 
been Southern blot (Southern, 1975) for DNA, Northern 
blot (Alwine et al., 1977) for RNA and Western blot 
(Towbin et al., 1979) for protein. Although an immense 
amount of information has been gathered using these 
techniques, it limits the user to probing their sample one 
factor at a time. With these tools, science tended towards 
a reductionist approach to understand the complexity of 
biology, simplifying models to individual genes or 
proteins. 
The nearly 13-year endeavor that was the Human Genome Project (HGP) predominantly used 
an automated version of Sanger sequencing (Sanger et al., 1977), a chain-termination method 
incorporating radioactively labeled dideoxynucleotides of each base pairP, which used 
fluorescent dyes to tag each nucleotide (Adams, 2008). The HGP revealed that the over 3 
billion base pairs of the human genome contained only approximately 20,500 protein-
encoding genes (Clamp et al., 2007; NIH National Human Genome Research Institute, 
2005). 
The current iteration is called next-generation sequencing (NGS), which refers to non-
Sanger-based high-throughput DNA sequencing technologies, where millions of DNA 
strands can be sequenced in parallel using the following general methodology: template 
preparation, sequencing and imaging, and data analysis (Grada and Weinbrecht, 2013).  
Sequencing the human genome brought with it not only the use of genomics to understand 
health and disease, but also a drive to generate technologies that increase the speed and lower 
the cost to do so. With the advent of more complex computing and data management, the 
‘omics’ revolution, which started with genomics, spawned a growing list of cell components 
treated to this high-throughput systematic approach, including transcriptomics, proteomics, 
lipidomics, metabolomics, epigenomics and pharmacogenomics. Instead of looking for a 
factor of interest, one could evaluate all factors in a sample at once, like taking a high-
resolution snapshot instead of searching for a pixel.  
                                                
P The four nucleotides found in DNA: adenine (A), thymine (T), cytosine (C) and guanine 
(G), form base pairs A-T and C-G. 
Figure 11: Crick's central dogma 
(blue) and special cases (red). 





Introduction to RNA-Seq 
Cells in the body contain the exact same DNA sequence and therefore the same genes 
(genome), but it is the expressionQ of these genes that determines the differences between 
cells of each tissue of the body. Transcriptomics is the study of all RNA molecules (mRNA, 
rRNA, tRNA and ncRNA)R produced by the genome of a specific cell or cell population 
under defined circumstances. The mRNA population represents the ‘active’ genes in a cell, 
whose transcripts are most likely on their way to instructing the synthesis of a specific 
protein, the major functional unit of a cell’s activity.  
Currently the most common method for gene expression analysis is quantitative real-time 
PCR (qPCR) (Gibson et al., 1996; Weis et al., 1992), where complementary DNA (cDNA) 
reverse transcribed from RNA is used as a template and is amplified in a polymerase chain 
reaction (PCR). Synthetic primers are designed towards the specific DNA fragment to be 
amplified by the PCR process. The qPCR reaction is quantified by detecting the intensity of a 
DNA probe generating a fluorescent signal. Although relatively cost-effective, qPCR only 
allows for one gene at a time to be analyzed in a group of samples, and the quality of results 
is highly dependent on the cDNA primer design.  
Gene expression microarrays allow for high-throughput analysis (Schena et al., 1995). Here, 
a library of cDNA probes is printed onto a surface and fluorescently labeled target sequences, 
which bind to the probe sequence, generate a signal. Limitations include the contents of the 
probe library and accounting for cross-hybridization of mRNA over multiple probes in the 
array.  
In 2008, RNA-Sequencing (RNA-Seq) was introduced as a way to directly sequence all 
mRNA in cells, and allowed for gene expression to be quantified (Cloonan et al., 2008; 
Mortazavi et al., 2008).  The basic RNA-Seq workflow starts with extracting RNA from a 
sample (tissue, cell pellet, single cells). Next is the cDNA library preparation, where 
poly(A)+ RNA (only mature mRNA ready for translation) is enriched from total RNA, is 
fragmented and is converted into a library of cDNA fragments with attached adaptors and 
barcodesS specific to each sample. The fragments are PCR-amplified, sequenced, aligned to a 
reference genome, and analyzed for many factors, including whole-transcriptome gene 
expression, isoform detect, and strand information (Wang et al., 2009). The abundance of 
target transcripts are indicated by read counts of that transcript, normalized for the RNA 
                                                
Q Expression: when, and how much of, the DNA ‘message’ is copied and made into a specific 
protein (molecules that perform the majority of cellular functions) 
R m: messenger, r: ribosomal, t: transfer, nc: non-coding 
S Barcodes: unique DNA sequences (also called indexes or tags) ligated to the cDNA 




length and the sequencing depth of the sample, with the unit RPKM (reads per kilobase per 
million)T.  
RNA-Seq provides quantitative approximations of the abundance of target transcripts in the 
form of counts. However, these counts must be normalized to remove technical biases 
inherent in the preparation steps for RNA-Seq, in particular the length of the RNA species 
and the sequencing depth of a sample. For example, expectedly, deeper sequencing results in 
higher counts, biasing comparisons between different runs with different depths. Similarly, 
longer transcripts are more likely to have sequences mapped to their region resulting in 
higher counts, biasing comparisons between transcripts of different lengths. 
Experimental considerations 
As is the case with effectively using any technique or technology, it is vital to know its 
limitations to appropriately apply its data to the broader context. There are many aspects to 
consider when planning RNA-Seq experiments, including the study design, sample 
preparation, sequencing and data analysis protocols (Kratz and Carninci, 2014). 
At the start of any experiment, irrespective of technique or technology, the experimental and 
control groups have to be assessed to ensure that as many variables as possible are accounted 
for. Examples of experimental considerations for RNA-Seq include ensuring cell-type 
homogeneity, consistent time points and sufficient sequencing depth.  
It is less of an issue when sequencing cell lines, but as variations of RNA-Seq are used for 
translational medicine where tissue biopsies are used, it is important to compare 
homogeneous samples since gene expression profiles differ greatly between cell types. There 
is currently a move away from bulk towards single-cell RNA-Seq in order to obtain a cell-
type-specific transcriptome instead of a tissue-specific one. Potential medical applications of 
this new avenue are discussed in the ‘Base pairs to bedside’ section. 
mRNA expression is inherently transient, as it changes depending on a cell’s response to both 
internal and external cues, therefore it is important to remember that RNA-Seq data only offer 
information of one point in time of a cell’s transcriptome. When comparing sample groups to 
control groups within and among experiments, variables should be considered, such as drug 
treatment vehicles or a patient’s age at the time of biopsy, especially important when studying 
pediatric diseases such as Alagille syndrome.   
RNA-Seq is a powerful tool to detect single nucleotide polymorphisms (SNPs) (Piskol et al., 
2013) or splice-site mutations, but its data will only provide information for expressed genes. 
For example, mutations in non-expressed genes cannot be detected and genetic markers can 
only be used if they are expressed (Schneeberger, 2014). Therefore, one must consider if and 
how RNA-Seq can address the experimental question. 
                                                
T RPKM = [# of mapped reads] / ([length of transcript]/1000) / ([total reads]/106) 
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Although often veiled in the ‘black box’ of Bioconductor packages (Huber et al., 2015) or 
Java applets, the analysis tools and statistical methods applied to RNA-Seq data are essential 
considerations for objective data interpretation. With a growing number of large repositories 
such as the Encyclopedia of the regulatory elements (ENCODE) (Rosenbloom et al., 2013) 
and The Cancer Genome Atlas (TCGA) (Robbins et al., 2013), uniformly analyzed data 
allows users to compile results from many sources, but this is difficult to maintain, due to the 
multitude of ever-evolving algorithms and pipelines. The least that should be done is 
providing detailed descriptions of the study samples and a clear pipeline of analysis 
methodology used for any published RNA-Seq data, apart from depositing data at the 
Sequence Read Archive (for raw sequence reads) (Leinonen et al., 2011) and the NCBI Gene 
Expression Omnibus (for processed gene expression values) (Barrett et al., 2013; Edgar et 
al., 2002).  
Species-specific sequencing 
Xenografting, elaborated in the section above of the same name, is a unique instance when 
the mixed-species nature of the sample can be used to glean biologically relevant 
information. A few previously published studies illustrated this: one in which cross-species 
hybridization of microarrays studied the human tumor transcriptome of brain metastasis in 
the mouse (Park et al., 2011), and another which used species-specific qPCR analysis to 
study the mouse angiogenic response across a panel of human tumor xenografts with known 
differences in vascular and stromal architecture (Farren et al., 2012). Aside from each 
technique being quite labor-intensive, neither approach allowed for a large-scale analysis of 
the transcriptomes from the two species. Recent reports have described related technologies 
to decode mixed-genome transcriptomes (Bradford et al., 2013; Conway et al., 2012; 
Raskatov et al., 2012; Rossello et al., 2013). Paper III presents our parallel effort in 
contributing a species-specific sequencing technology, which we call S3 (‘S-cube’), using 
RNA-Seq to quantify all mRNA transcripts in human tumors and surrounding mouse stroma, 
in an unbiased manner.   
Xenograft models inherently provide many of the structural and molecular cues necessary for 
a tumor to exhibit characteristic growth as in the human body, but this mélange of cell types 
contributes to the difficulty in interpreting the data to assign transcriptional changes to 
particular cell types of the same species (as mentioned in Experimental considerations 
above). To supplement RNA-Seq data from xenografts, our S3 approach can be used to study 
the interaction of individual components of the stromal compartment on tumor cells, by co-
culturing these two cell types in a dish or embedded in a synthetic ECM. Apart from tumor 
biology, basic molecular pathway analysis can benefit from a cleaner read-out of signal-
sending and signal-receiving cells, an example of which we also present in Paper III. 
‘Base pairs to bedside’ 
The translation of basic science sequencing endeavors to biomedical applications, or ‘base 
pairs to bedside’ (Green et al., 2011), is the concept of effectively using NGS technologies to 
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get unprecedented insight into the expanse of biology that covers the human experience. A 
therapeutic ‘holy grail’ is personalized medicine, and genomic medicine is an enticing 
chalice.  
Applications of NGS are now routinely used for many studies, ranging from basic to 
biomedical research. Developmental and evolutionary biologists use whole-genome 
sequencing (WGS) for comparative biology studies; clinical researchers use WGS to identify 
regulatory elements and RNA-Seq for gene expression studies to understand pathological 
processes; epidemiologists identify novel virulence factors by studying the sequences of 
bacterial and viral species; and microbiologists study microbiomes of environments and 
organisms at an unprecedented level. Whole-exomeU sequencing has been developed as a 
rapid tool for gene and mutation discovery that clinicians use to directly diagnose a patient 
displaying symptoms with an unidentified genetic cause. When specific genes or genomic 
regions are suspected in a disease, targeted sequencing is a more rapid and less analysis-
intensive approach to ‘target hotspots for disease-causing mutations’ (Grada and Weinbrecht, 
2013). 
Crowned the method of the year for 2013 (Nature Methods Editorial, 2014), Single-cell 
sequencing is not only complementary to existing NGS methods, but is also a discovery tool 
able to capture the diversity of individual cell states within a seemingly homogenous tissue, 
and identify yet-unknown cell types of the developing and diseased body. Scientists have 
studied entire organisms, the organs themselves and their comprising tissue, but can now look 
forward to peering into each cell itself, relating it to its neighborhood or community, and not 
just the entire cell population. For example, imagine a clinician able to identify the 
‘pathology-important cells’ (Eberwine et al., 2014) after single-cell sequencing a patient’s 
tissue biopsy and prescribing a drug cocktail that has been designed to target specific disease-
driving factors.  
With high-throughput advances and falling prices in NGS technologies, it is absolutely 
exciting to utilize these techniques to gain higher resolution of your organism or system of 
interest, but first and foremost it is essential to consider the limitations of each technology in 
order to use it as a tool, along with other tools, to understand your system in context.  
 
…one of these key principles of science is that no study is definitive of any piece of evidence 
of any finding on its own. We are in a process of uncertainty reduction when we are doing 
science, and each study contributes additional evidence to reduce that uncertainty.  
– Prof. Brian Nosek 
Center for Open Science  
(Science Podcast, 2015) 
                                                






The overall aim of the research presented in this thesis is to investigate dysregulated Notch 
signaling in two diseases where this cell-contact-dependent communication system is 
implicated: breast cancer and the liver disease of Alagille syndrome (AGS). We focused on: 
• A mechanism where hyperactivated Notch signaling crosstalks with other signaling 
pathways in breast cancer. 
• A method to separate transcriptional information using species-specific differences of 
the cell types involved: tumor and stromal tissue in breast cancer xenografts, and 
signal-receiving cells with signal-sending cells affected by an AGS-like mutation. 
• A characterization of a Jagged1 mutant mouse as a potential model for the liver 










Experimental tools used in this thesis: 
Paper I: immunohistochemistry of patient breast tumors, qPCR, p53-luciferase, IL-6 
promoter luciferase, κB-luciferase, tamoxifen-induced expression plasmid, Western blot, 
transfection, gene silencing by siRNA targeting, immobilized ligand assay, co-culture assay, 
adenoviral infection, ELISA, microarray, analyzing published data sets 
Paper II: transfection, 12xCSL-luciferase, immobilized ligand assay, co-culture assay, 
mammary fat pad xenografting, cDNA library preparation, RNA-Seq, bioinformatics 
Paper III: immunohistochemistry of mouse liver, serum chemistry analysis, transfection, 
qPCR, 12xCSL-luciferase, biliary organoid culture, immobilized ligand assay, co-culture 




PAPER I: NOTCH & IL-6 IN BREAST CANCER 
Notch signaling is often hyper-activated in breast cancer, but how this influences the course 
of the disease is still relatively unknown. We discover a role of non-canonical Notch 
signaling in activating the JAK/STAT cascade via IL-6, and identify a role for p53 in the 
Notch and cytokine response.  
IL-6 acts as a pro-inflammatory cytokine, secreted by B cells, T cells and macrophages to 
stimulate an inflammatory response to tissue damage. IL-6 signaling is dysregulated in a 
variety of diseases, for example breast cancer, where high serum levels of IL-6 in patients 
correlate with a poor clinical prognosis (Sethi et al., 2011; Wang et al., 2005). 
We analyzed a panel of breast tissue from patients for expression of markers of basal 
(CD44high, CK5/6high, ER-, PR-) or non-basal breast cancers (CD44low, CK5/6low, ER+, PR+), 
and found that the basal-type breast cancers expressed higher levels of nuclear Notch1 ICD 
(N1ICD), an indication of active Notch signaling, compared to the non-basal-type breast 
cancers. Studying published patient transcriptome data (Pawitan et al., 2005), we also found 
elevated IL-6 and JAG1 mRNA expression in basal, compared to luminal, breast cancers. In a 
panel of breast cancer cell lines in vitro, active Notch signaling lead to increased IL-6 mRNA 
levels in basal-like (including MDA-MB-231), significantly more than in luminal (including 
MCF7), breast cancer cell lines.  
We went on to study the link between Notch signaling and IL-6 in breast cancer, in the basal-
type breast cancer cells MDA-MB-231, and observed that Notch signaling upregulates IL-6 
mRNA and protein expression in two assays: (1) infection with adenoviral vector expressing 
NICD, and (2) immobilized ligand stimulation, and this upregulation could be abrogated by 
DAPT. Notch seems to regulate IL-6 expression transcriptionally, as nascent (pre-splicing) 
and mature (spliced) IL-6 mRNA was upregulated to the same extent. This transcriptional 
increase in turn led to increased protein levels of IL-6 in the cell culture medium, as 
determined by ELISA (enzyme-linked immunosorbent assay). IL-6 produced in response to 
upregulated Notch signaling in MDA-MB-231 cells activated JAK/STAT3, and the 
downstream target Bcl-xL. Conditioned medium from MDA-MB-231 cells over-expressing 
N1ICD was sufficient to induce pSTAT3 in naïve MCF7 cells, and this induction was 
blocked by IL-6 blocking antibody. This data together points to IL-6 as a novel Notch target 
gene in basal breast cancer cells, and the Notch-induced increase in IL-6 expression results in 
autocrine and paracrine activation of JAK/STAT signaling. 
To identify the attributes of basal-like breast cancers causing their susceptibility to Notch-
mediated IL-6 upregulation, we studied two components, ER and p53 status, differing in 
MCF7 (ER+, wild type p53) and MDA-MB-231 (ER-, mutated p53) cells. In MDA-MB-231 
cells, re-introduction of ERα did not alter IL-6 induction, although it did activate an estrogen-
responsive-element-luciferase reporter construct. In contrast, IL-6 expression dramatically 
reduced with the introduction of wild-type p53, while HES1 expression did not change. 
Mouse embryonic fibroblasts genetically deficient for p53 showed an Il-6 upregulation when 
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overexpressing N1ICD, which was abrogated upon introduction of wild type p53. MCF7 
cells transfected with a mutated form of p53 now showed IL-6 upregulation when the N1ICD 
was overexpressed. Therefore, these data convinced us that the Notch-mediated IL-6 
upregulation we observed was dependent on the cellular p53 status.  
The conventional image of the Notch pathway is activating Notch signaling leads to cleavage 
of the Notch receptor, where the intracellular portion of the receptor then translocates to the 
nucleus and upregulates downstream genes. In this work, we found evidence that Notch 
signaling regulates IL-6 in an atypical way, that cytoplasmic N1ICD also could upregulate 
IL-6 transcriptionally. Also, NICDΔRAM activated IL-6 but not HES1 in MDA-MB-231 
cells, and dnCSL did not interfere with N1ICD-mediated IL-6 upregulation. Therefore, we 
deduce that non-canonical CSL-independent Notch signaling is implicated in regulating IL-6.  
We found that the Notch pathway communicating with the NF-κB cascade led to 
transcriptional activation of IL-6 in an unconventional manner, requiring IKKα and IKKβ 
function but not canonical NF-κB signaling. Pharmacologically inhibiting IKKβ, or siRNA 
knockdown of IKKα or IKKβ, reduced Notch-mediated IL-6 upregulation. TNF-α and 
LPS, but not the N1ICD, activated a κB-luciferase reporter construct, used to monitor 
downstream NF-κB signaling.  
To test whether Notch-mediated IL-6 upregulation could affect tumor-associated 
macrophages, we exposed RAW264.7 cells, a mouse macrophage-like cell line, to 
conditioned medium from Notch-activated MDA-MB-231 cells and saw elevated levels of 
phosphorylated STAT3. Treating RAW264.7 cells with recombinant IL-6 increased Notch1 
and Jag1 expression, and transfecting N1ICD or NICDΔRAM increased Il-6 mRNA 
expression. As Il-6 and Notch signaling are reciprocally upregulated in RAW264.7 cells, 
these data suggest the existence of a feed-forward loop for maintaining Notch and IL-6 
expression in macrophages. 
In sum, we show that Notch activates IL-6 secretion and JAK/STAT signaling, p53-
dependently but CSL-independently via IKKα and IKKβ. Our data link Notch and the tumor 
inflammation microenvironment in breast cancer, where tumor-stroma cytokine interactions 







PAPER II: S3 RNA-SEQ TO STUDY TUMOR-STROMA 
INTERACTIONS 
It is becoming increasingly evident that not only the genetic aberrations in the tumor are 
important for tumor development and patient prognosis, but also the interplay between the 
tumor and the surrounding tissue, the stroma. It is likely that there is a complex interaction 
between the tumor and stroma at many different levels, and it would be important to better 
understand the molecular consequences of this at a genome-wide transcriptome level. To 
address this in a breast cancer model, we use the xenografting strategy of mammary fat pad 
injection to take advantage of the species difference (i.e. human cells introduced into the 
mouse), and carry out RNA-Seq of both the primary (human) tumor and the surrounding 
(mouse) stroma. We call this new strategy species-specific sequencing (S3). With S3, both the 
tumor and stroma transcriptomes can be obtained with minimal manipulation of the tissue 
before analysis, and the gene regulation events in both tumor and stroma can be analyzed for 
the vast majority of genes based on their species-specific differences. 
The S3 protocol entails (1) obtaining material containing mixed-species cells or tissue stored 
in conditions to stabilize RNA, (2) disrupting and homogenizing the tissue, extracting total 
RNA, making a cDNA library, (3) sequencing, demultiplexing each sample, converting data 
to FASTQ format, aligning sequences to genomes of both species with STAR software, 
discarding overlapping reads after species separation, and calculating gene expression levels 
from normalized data. 
In order to establish S3 as a technology, we first needed to evaluate the ability to separate 
mouse and human cDNA transcripts after RNA-Seq of a mixed sample in silicoV. The 
strategy is to align all sequence reads to both genomes and discard the overlapping reads, 
which are conserved and therefore cannot be distinguished between the two species. After 
testing three human and three mouse samples from previously published RNA-Seq data, we 
found that approximately 0.15 - 0.30% of the reads from one species were mapped to the 
other species’ genome, rendering them un-available in a mixed scenario.  This left over 99% 
of the reads able to be separated by species.  
We were curious if our S3 pipeline could be applied to a three-species comparison, which 
could be helpful in studying, for example, xenografted rat cancer-associated fibroblasts 
(CAFs) with human cancer cells into a mouse to understand tumor-CAF-stroma interactions. 
In theory, the same strategy of aligning reads to all genomes and discarding the overlapping 
reads can be applied, but when doing so we found many rat reads misassigned as mouse, 
although mouse reads were not misassigned as rat. This misassignment of rat reads could be 
due to the lower quality of the rat genome assembly or annotation, compared to the well-
established human and mouse genomes. As genomes from more organisms are better 
                                                
V in silico: in silicon, meaning via computer simulation 
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sequenced with improved technologies, S3 can be used to decipher transcriptome changes in 
complex experimental settings. 
It is an open question in the Notch field as to how a ligand ought to be presented when 
designing experiments in study biologically relevant pathway induction, also discussed in the 
ligand-receptor interaction section in the thesis introduction. To shed light on this, we put the 
S3 technology to use in cell culture experiments to decode transcriptional effects of the mode 
of ligand presentation in Notch signaling. There are essentially two ways to activate ligand-
induced Notch signaling experimentally: placing receptor-expressing cells on immobilized 
ligand fragments, or co-culturing receptor-expressing cells with ligand-expressing cells. We 
use human MDA-MB-231 cells, which physiologically express high levels of NOTCH1, as 
the receptor-expressing cells, and use mouse 3T3-L1 cells transiently transfected with DLL4 
as the ligand-expressing cells or immobilized Fc-DLL4 ligand. Activation of Notch signaling 
after each mode of ligand stimulation and abrogation by the γ-secretase inhibitor DAPT was 
verified using a 12xCSL-luciferase reporter assay. Studying the transcriptomes of the 
receptor-expressing cells after co-culture or on immobilized ligand, we find marked 
differences. The ‘Notch signatures’, genes upregulated after ligand presentation but reduced 
after DAPT treatment, were compared. Both signatures shared only one common gene, 
exemplifying how different the transcriptional output can be depending on how a ligand is 
presented. The co-culture and immobilized ligand assays also differed in the intensity of 
activation of selected canonical Notch target genes and to their sensitivity to inhibitor, with 
cells on immobilized ligand showing greater target gene activation and responsiveness to a 6-
hour DAPT treatment. The co-culture assay may seem less responsive in a traditional Notch 
sense, but this could be due to the fact that this assay set-up is more ‘noisy’, with responding 
signaling factors from the ligand-expressing cell, but may be more physiologically 
representative. This distinction would need to be investigated further, with additional time 
points and other Notch ligands.  
The technique that inspired the S3 approach, engrafting human tumor cells into mouse 
mammary tissue has been valuable to understand breast tumor growth and to study 
differences in breast cancer subtypes in vivo. We wanted to test the ability of S3 to capture 
transcriptome changes in both the tumor and stroma of xenografted luminal (MCF7) and 
basal-type (MDA-MB-231) breast tumor cells. There were several differing parameters 
between the two tumor models, including the mouse background, mouse immune status, 
status of mammary fat-pad clearing and proportion of tumor to stroma excised. In spite of 
this, our technique is able to capture the distinct transcriptomes of the MCF7 and MDA-MB-
231 cells grown in vivo compared to cells grown in a dish, and most exciting, it is able to 
separate the stromal transcriptomes of each xenografted subtype.  
In conclusion, we show that our bioinformatics-based transcriptome analysis technique S3 
faithfully assigns 99% of the genes to be of mouse or human origin in silico, in cultured cells 
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and in vivoW. Many other questions in breast cancer can be addressed using S3, including 
studying cells with different levels of Notch expression, xenografting mice with different 
genetic backgrounds (e.g. p53-deficiency) to explore the consequences for stroma and tumor 
expression, comparing transcriptomal changes between a primary tumor and its metastatic 
tumor, xenografting primary breast cancer cells representing well-defined subsets of breast 
cancer (e.g. ER+/ER-, PR+/PR-, BRCA+/BRCA-), and xenografting human cell lines that form 
tumors at similar rates but are likely to have different effects on the surrounding stroma (e.g. 
stromal metaplasia, invasion/metastatis, angiogenesis). Essentially, S3 can be done on any 
system with samples containing cells from multiple species, as long as each species’ genome 


















                                                
W in vivo: in living (Latin), refers to studying molecules or cells in an organism 
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PAPER III: NODDER, A MOUSE MODEL OF ALAGILLE SYNDROME 
The physiological effects of a gene mutation during development manifest itself in tissues 
where the gene has a functional role, not compensated for or rescued by complementary 
factors. Studying models lacking normal gene function help us identify the essential factors 
necessary for normal organ formation and maintenance, and insights can lead to clinical 
interventions. Modeling developmental disorders, like Alagille syndrome (AGS), is all the 
more challenging due to the multiple organ systems affected in these diseases. 
Previous attempts to model AGS have proven difficult since Jag1 knockout mice do not 
survive past embryonic day (E)11.5 due to vascular defects (Xue et al., 1999). Mouse models 
for AGS-associated liver disease (described also in the AGS models section) have included a 
Jag1/Notch2 double heterozygous mouse (Lozier et al., 2008; McCright et al., 2002), 
conditional ablation of Jag1 in the portal vein mesenchyme (Hofmann et al., 2010), and a 
Jag1 heterozygous mouse (Thakurdas et al., 2015). These models help our understanding of 
AGS-associated liver defects, but also have several shortcomings: the first model requires 
both mutated Jag1 and Notch2 in displaying AGS-like phenotypes, while NOTCH2 mutation 
are observed in only 1% of AGS patients; the second model does not recapitulate AGS 
features in other organs; and the third model does not exhibit jaundice from bile duct paucity, 
and other affected organs were not reported.  
We characterize a mouse model (Jag1Ndr/Ndr) with a missense mutation in the gene encoding 
Jagged1 (H268Q, named Nodder), which presents many AGS-like phenotypes including 
liver, heart, lens and kidney pathologies in the mouse. This mutation results in intrahepatic 
bile duct paucity in these mice, and we identify biliary morphogenesis and maintenance, 
rather than biliary differentiation, to be disrupted. RNA-Seq of Alagille patient liver biopsies 
shows decreased expression of polarity markers compared to non-Alagille liver biopsies. We 
also begin to address the molecular mechanism by which this mutation acts, showing a 
transcriptional hypomorphic Notch signaling response and receptor-selective interaction with 
Notch2 and Notch3, but not Notch1.  
The Nodder mice were originally developed in a C3H background, where the homozygous 
mutation is embryonically lethal, but the Jag1Ndr/Ndr mice survive into adulthood when 
outbred to a C3H/C57BL6 mixed genetic background, though far fewer than the expected 
25% Mendelian ratio survive and those that do are of a considerably smaller size. 
The surviving Jag1Ndr/Ndr mice present with jaundice from postnatal day (p)1, the first 
indication of a liver phenotype. These mice display both atrial and ventricular septal defects, 
also observed in AGS patients, at E15.5 and p0, and progressively irregular eye morphology 
from E13.5. The Jag1Ndr/Ndr mice also exhibit renal symptoms of jaundiced and atrophied 
kidneys at p10, and altered craniofacial proportions. 
Immunohistochemistry with staining for WGA (wheat germ agglutinin; marker of portal 
mesenchyme) shows a near-complete loss of bile ducts in the Jag1Ndr/Ndr mice at p10, and 
expression analysis from whole-liver extracts reveals a significant downregulation of the 
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Notch target gene Hes1 and the bile duct determinant Hnf1b (Hepatocyte nuclear factor 1-β). 
Expression of Sox9 (Sry-related HMG box 9; marker of biliary cells in the developing liver) 
and developmental markers along the hepatoblast to hepatocyte lineage were not affected as 
assessed by qPCR, RNA-Seq and immunohistochemistry. In Jag1Ndr/Ndr mice that survive to 
adulthood, the jaundice seen at neonatal stages is not present, and pan-cytokeratin reveals bile 
ducts, although with abnormal morphology. ASMA (α-smooth muscle actin; marker of 
vascular smooth muscle cells) staining shows an absence of hepatic arteries. Blood serum 
analysis for liver function reveals no significant difference between adult Jag1+/+, Jag1+/Ndr 
and Jag1Ndr/Ndr mice in the enzymes and metabolites tested.  
To further investigate if the Jag1Ndr mutation caused morphogenesis or differentiation defects, 
we cultured biliary organoids (protocol summarized in Rise of the organoids section) from 
Jag1Ndr/Ndr and Jag1+/+ mice. Organoids from isolated bile duct fragments of Jag1Ndr/Ndr mice 
did not thrive as well as those from Jag1+/+ mice, and some abruptly collapsed after 5-6 days 
in culture, indicating compromised structural stability, although Notch2, Hes1, Hnf4a, Sox9 
and Hnf1b expression were not significantly altered in organoids of Jag1Ndr/Ndr mice. A 
similar structural-collapse phenotype was seen in human Alagille organoids (Huch et al., 
2015). 
RNA-Seq of AGS patient liver biopsies does not show a decrease in biliary markers (KRT19, 
HNF1B, SOX9), but several polarity markers of the apical face of biliary cells are lost. 
Although not transcriptionally downregulated in the patient biopsies, ZO-1 (Tight Junction 
Protein Zona Occludens-1) does not show normal localization to intercellular tight junctions 
in the biliary structures of adult Jag1Ndr/Ndr mice. 
To explore the effects of the Nodder mutation on Notch signaling at the molecular level, we 
employed a co-culture strategy of human HEK293 Flp-InX cells stably expressing wild type 
Jagged1 ligand (Jag1WT) or Jag1Ndr cultured with mouse myoblast C2C12 control cells or 
stably expressing the full-length Notch1 receptor (C2C12-FLN1), and carried out the S3 
pipeline (developed in Paper II) to obtain the transcriptomes from the receptor-expressing 
cells co-cultured with Jag1WT or Jag1Ndr. A principal component analysis (PCA), of C2C12 
control and C2C12-FLN1 seeing HEK293 control, Jag1WT or Jag1Ndr, shows the 
transcriptome landscape of C2C12 and C2C12-FLN1 resulting from interaction with Jag1Ndr 
mid-way between the transcriptomes resulting from interaction with Jag1WT or control cells, 
although more pronounced in the C2C12-FLN1 cells. Also, several established Notch target 
genes show intermediate expression levels from interaction with Jag1Ndr, compared to the 
levels observed after interaction with Jag1WT or control cells. These data allude to Jag1Ndr 
acting as a Notch-activation hypomorph, with reduced but not complete loss in gene 
expression. Since this mutation is not signaling-dead, it indicates that Notch signaling is 
                                                
X Flp-InTM system (ThermoFisher Scientific): allows integration and expression of your gene-
of-interest in mammalian cells at a specific genomic location; used for generating constitutive 
expression cell lines. 
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proceeding, and indeed, Jag1Ndr exhibits Notch receptor-specific binding to Notch2 and 
Notch3, but does not bind to Notch1.  
Overall, we validate the Jag1Ndr/Ndr mouse as a model of AGS-like phenotypes in the liver, 
heart, lens and kidney, which are likely caused by hypomorphic Jagged1 signaling, and 
implicate biliary cell polarity as a target of Notch signaling, dysregulated in our model and in 

























Combination therapy is a cancer treatment strategy to overcome hurdles, such as resistance 
associated with single-agent therapies and toxicity from high drug dosage. Because of off-
target effects and intestinal drug toxicity, γ-secretase-based Notch pathway inhibitors seem to 
be less helpful as a mono-therapy as first hoped (Brennan and Clarke, 2013), but there are 
several GSIs, including MK0752 and RO4929097 (ClinicalTrials.gov identifiers 
NCT00106145 and NCT01151449, respectively), in early clinical trail phases to test safety 
and efficacy (Andersson and Lendahl, 2014). Along these lines, the Janus kinase inhibitor 
ruxolitinib combined with the HER2/neu blocking antibody trastuzumab is being tested in a 
Phase I/II clinical trail to treat metastatic HER2+ breast cancers (ClinicalTrials.gov identifier: 
NCT02066532). In Paper I, an IKKβ inhibitor (TPCA-1) abrogated Notch-mediated IL-6 
expression, pointing to another potential drug target for breast cancer, but no IKK-β 
inhibitors have reached clinical development, primarily due to concerns over hepatic toxicity 
seen in IKK-β knockout mice (Deng et al., 2015). 
With the non-canonical Notch and IL-6 link established in HER2- MDA-MB-231 cells in 
Paper I, we can test new therapeutic targets on breast tumor cells, tapping into existing drug 
treatments for inflammatory diseases, such as tocilizumab (Actemra®), a humanized 
monoclonal antibody against the IL-6 receptor (IL-6R), used mainly for the treatment of 
rheumatoid arthritis (Hennigan and Kavanaugh, 2008). For instance, it would be interesting 
to test the therapeutic effects of a DAPT and tocilizumab combination treatment on MDA-
MB-231 xenografted tumors, and analyze drug-induced transcriptional changes using the S3 
pipeline. 
The S3 technology could also be used to further investigate tumor-CAF-stroma interactions, 
in a three-species approach similar to that tested in Paper II, but instead of xenografting 
human primary breast cancer cells with CAFs from one mouse background into a mouse of 
another background, such as CAST/EiJ and C57BL/6J, a combination successfully used in 
(Deng et al., 2014). 
Emergent technologies, such as single-cell RNA-Seq and targeted genome editing by 
CRISPR-Cas9 (Jinek et al., 2012) could provide the high-throughput, high-resolution 
platforms necessary to be able to capture the pleiotropic Notch pathway’s context-dependent 
signaling diversity. Single-cell sequencing of biopsies from Paper III’s Jag1Ndr/Ndr mouse 
livers and AGS patients’ livers would allow us to obtain transcriptomes of each represented 
cell type to detect nuances lost in the traditional bulk sequencing method. We can also 
venture to rescue the structural collapse we see in Jag1Ndr/Ndr biliary organoids, or by 
correcting the Nodder mutation in the organoids using CRISPR-Cas9 targeted genome 
editing. This rescue could also be attempted in organoids from AGS patients (Huch et al., 
2015), as was successfully done in organoid cultures from colon stem cells of cystic fibrosis 
patients (Schwank et al., 2013). Another interesting avenue is to perform immune 
characterization of the Jag1Ndr/Ndr mouse, as immune dysregulation is a new feature of the 
AGS phenotype (Tilib Shamoun et al., 2015).  
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POPULAR SCIENCE SUMMARY 
Rube Goldberg was an American inventor 
and cartoonist known for depicting 
creations such as the ‘Self-Operating 
Napkin’ (Figure 12), a deliberately over-
engineered contraption to accomplish a 
simple task, like wiping ones mouth, 
usually including a chain reaction. This led 
to coining of the term ‘Rube Goldberg 
machine’Y. 
A signaling pathway can seem like a Rube 
Goldberg machine at first glance, but this complex sequence of events is inevitable, given 
that a cell has a fixed set of machinery that must be reused to generate and perceive signals 
from an ever-evolving environment. 
For me, health and disease are reflected with ‘the Goldilocks principle’, when too much or 
too little of anything leads to disease and ‘just right’ brings the balance of health. Since the 
day we were conceived, our bodies have tried, and continue today, to maintain a healthy 
balance, ‘a homeostatic environment’, that each cell should be in the right place and doing the 
right thing. DNA is the instruction manual that keeps our machine running. Depending on 
what the cell needs, RNA takes sentences of instructions and strings them together to make 
proteins, which have specific functions and carry out most activities of the cell. If words are 
misspelled in the manual, the resulting protein can be incorrectly made, and depending on 
which instructions are affected, this can cause the cell to copy itself uncontrollably, which is 
what is known as cancer. 
My PhD studies have concentrated on two diseases brought about by damaged DNA, breast 
cancer and the lesser known genetic disease Alagille syndrome, which in its most severe 
forms leads to heart and/or liver failure, requiring transplantation. What ties these two 
diseases together is the protein Notch. Notch is a protein displayed on the surface of cells of 
the body that help the cells to decide what is going on in their environment. Like reaching out 
to shake hands, Notch reaches out trying to find partners to interact with. When Notch binds 
(shakes hands) with a neighboring cell the Notch signaling pathway becomes active in the 
Notch-displaying cell, typically either causes the cell to decide to divide to produce two cells 
or could tell the cell to turn into a different type of cell. In some forms of breast cancer there 
is too much Notch signaling, there is too much hand shaking, too many cells are deciding that 
they need to divide to produce more cells. In Alagille syndrome there is not enough Notch 
                                                
Y Rube Goldberg machine: a deliberately over-engineered device, usually including a chain 
reaction, designed to perform a simple task in a complicated fashion; named after American 
cartoonist and inventor Rube Goldberg (1883–1970). 




signaling, not enough hand-shaking, and certain types of cell that require a certain amount of 
Notch signaling are not produced in the developing baby making those organs weak.   
In the first paper in my thesis (Paper I), I find that Notch signaling drives cancer cells not 
only to produce more cancerous cells but makes the cells produce another protein called IL-6, 
which causes inflammation. The ability of Notch signaling to cause inflammation in this way 
has never been shown and is surely a driver in the creation of the toxic environment in which 
cancer cells thrive. In my second paper (Paper II), I investigate how the communication 
between cancerous cells and ‘healthy’ cells (cells without damaged DNA), that surround 
cancerous cells, may respond to proteins produced by the cancer (like IL-6) to create an 
environment that actually promotes growth of the DNA damaged cancerous cells. It would be 
helpful to understand what the tumor (DNA damaged cancerous cells) and stroma 
(surrounding cells without DNA damage) are ‘saying’ to each other, in hopes to find a way to 
cut or change their communication. In order to do this we developed a method, based on the 
differences between the DNA of humans and mice, for ‘reading’ the ‘internal thoughts’ of 
human tumor cells injected into the mouse mammary gland. We showed that this new tool 
can be used to study human tumors grown in mice, and perhaps discover new signals or 
proteins that are druggable (for which anti-cancer drugs can be developed). 
In Paper III of this thesis, I show that a single ‘misspelling’ in a mouse gene called Jagged1 
can cause a disease in the mouse similar to the human condition Alagille syndrome. It is 
fascinating and heartbreaking at once to know that just a single ‘typo’ in a book with 3 billion 
characters could lead to such a severe condition requiring a liver and/or heart transplant, 
however being able to model this human disease in mice gives us great opportunities for 
understanding the disease and developing therapies for it. The Jagged1 gene actually makes 
one of the proteins that Notch ‘shakes hands’ with. The Notch protein on one cell binds to 
proteins called Jagged or Delta on neighboring cells to activate Notch signaling. We show 
that this single misspelling in the Jagged1 gene decreases the amount of Notch signaling in 
the developing baby mouse, which causes the liver to develop abnormally, just like in the 
human disease. So even though there is actually nothing wrong with the Notch protein, the 
Jagged1 protein in the developing liver is unable to reach out and grab on to the Notch 
protein in a manner sufficient for creating a normal liver. 
As scientists, we will endeavor to continue in simplifying the biological world away from 
‘Rube Goldberg Machines’, removing the daunting and confusing unknowns that obscure the 
understanding of, and thus treatment potential for, human diseases. With each scientist, each 
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